Medical AI pause before real-world clinical testing: why simulation is no longer enough

Since the launch of the ChatGPT model in November 2022, generative AI tools have infiltrated clinics and medical centers at an accelerating pace and on a large scale. These systems are no longer merely research experiments in labs; they have become a daily resource relied upon by hundreds of millions, as more than 230 million people worldwide pose health-related questions each week to conversational AI models. In less than four years, thousands of studies have emerged testing and evaluating the use of general-purpose and specialized systems in health care, to the point that scientific journals now publish roughly three review papers per day on AI tools in clinical medicine.

This presence goes beyond direct consultations to the core of medical procedures; algorithmic systems now handle complex administrative tasks, order laboratory tests, assist physicians in writing prescriptions, interpret X-ray, MRI and CT images, and also help diagnose rare diseases. Yet this rapid expansion puts regulators faced with a genuine dilemma: how can they verify that these innovative medical products truly deliver what their developers claim once they move into examination and treatment rooms?

Clinical reality reveals a troubling gap in the evaluation methodologies currently used.The U.S. Food and Drug Administration and its international counterparts grant licenses for devices and medical products according to a graduated risk scale. While makers of bandages rely on self-declaration of quality standards, and evaluation tools such as medical stethoscopes require third-party laboratory testing, diagnostic products that influence medical decisions are subject to field tests and clinical trials comparable to drug evaluation pathways. However, a systematic review published in Nature Medicine in March 2026 uncovered a concerning reality: of roughly 4,600 research papers on AI tools in clinical medicine, only 23 % were based on real-world patient data, and prospective randomized studies accounted for no more than 19 clinical trials.

Developers currently rely on testing their models in one-off virtual simulation scenarios, where model performance is judged by human physicians confronting the same fabricated case, isolated from real-world workload pressures and case diversity. Studies that have compared specialized medical models with general-purpose models have produced mixed results on whether specialized systems indeed achieve higher accuracy. Risks are amplified by the fact that companies do not solicit patient opinions on accepting the integration of such software into their care plans. The danger is not limited to diagnosis; tools that record and summarize physician-patient conversations influence clinical decisions, necessitating rigorous scrutiny comparable to that imposed on autonomous vehicles, which undergo thousands of hours of supervised testing on real streets because the cost of an error is catastrophic.

Regulatory shift has begun to make pre-registered field trials a prerequisite for approval.The FDA opened a public comment period with a consultation paper released in August 2026 to examine regulation of generative-AI-based medical devices, setting 19 October 2026 as the deadline for submissions. At the same time, researchers in a Nature Medicine study call for pre-registered clinical trials to become a binding standard for intelligent medical software, just as they are for vaccines and drugs, emphasizing that data transparency and testing in real-world settings are non-negotiable principles.

This trajectory has practical implications for hospital executives and chief technology officers in the Gulf, Egypt and the Arab Levant. The rush to embed voice-summarization assistants and imported radiology-triage systems into electronic health records will soon meet tightened compliance requirements. As a medical-procurement or digital-transformation decision-maker, you should note that relying on virtual-lab results or vendors’ marketing claims will no longer suffice; on-site validation using local patient data will become a mandatory financial and procedural condition before contracting. Local clinical teams will also need to demand full transparency from vendors about the sources of clinical data and verify that models are suitable for the actual case mix in regional hospitals rather than trusting Western simulation figures.

We at the editorial board believe that health-care safety tolerates no laxity or haste. Algorithmic software that guides diagnosis and participates in treatment decisions cannot be treated with less rigor than drugs or autonomous vehicles; the true benchmark for model performance is not its behavior in sterile simulation environments but its ability to safeguard patient lives and safety in the heart of real clinical practice.